Changes

BCR (view source)

Revision as of 12:05, 22 June 2018

1,324 bytes added , 12:05, 22 June 2018

→‎Cancer Category/Type

Line 19: Line 19:

==Cancer Category/Type==

−

Chronic Myeloid Leukemia (Chronic Myelogenous Leukemia)

+

'''[http://www.ccga.io/index.php/Chronic_Myeloid_Leukemia_(CML)_with_t(9;22)(q34.1;q11.2);_BCR-ABL1 Chronic Myeloid Leukemia]''' (also referred as (Chronic Myelogenous Leukemia)

−

Acute ~~Lymphoid~~ Leukemia

+

More than 90% of patients diagnosed with Chronic Myeloid Leukemia bear a Philadelphia chromosome t(9;22)(q34.1;q11.2), which is a reciprocal translocation between chromosome 22 (BCR locus) and chromosome 9 (ABL1 locus (1, also see '''[http://www.omim.org/entry/613065 OMIM]'''). The Drug Imatinib mesylate, also known as Gleevec, was the one of the first molecularly developed drugs, and has a remarkably high success rate in treatment of patients with Chronic Myeloid Leukemia (5)

+

'''[http://www.ccga.io/index.php/Acute_lymphoblastic_leukaemia_(ALL) Acute Lymphoblastic Leukemia]'''

+

Approximately 20% of patients (25 - 30% of adult and 2 - 10% of children) diagnosed with Acute Lymphoblastic Leukemia bear a Philadelphia chromosome t(9;22)(q34.1;q11.2), which is a reciprocal translocation between chromosome 22 (BCR locus) and chromosome 9 (ABL1 locus) (1, also see '''[http://www.omim.org/entry/613065 OMIM]'''). Treatment of Acute Lymphoblastic Leukemia patients with Gleevec do not have the same success as Chronic Myeloid Leukemia patients treated with Gleevec, as the genomic instability of ALL cells contribute to point mutations arising in the BRC-ABL kinase domain, leading to resistance to Gleevec (4).

==Gene Overview==

Brian.Davis

436

edits